Document is current

Article History

Received: 22 April 2021

Accepted: 6 October 2021

First Online: 29 November 2021

Declarations

:

: This study was approved by the University of British Columbia-BC Cancer Research Ethics Board. Consent to participate was not required for this retrospective study of de-identified administrative data, in accordance with British Columbia’s Freedom of Information and Protection of Privacy Act (FIPPA).

: Consent for publication was not required for this retrospective study of de-identified administrative data, in accordance with British Columbia’s FIPPA.

: Marco A. Marra reports no conflicts of interest. Deirdre Weymann co-directs IMPRINT Research Consulting and has consulted for Roche Canada. Janessa Laskin has received honoraria for academic talks from Roche Canada, Pfizer Canada, Astra-Zeneca Canada, and Eli Lilly Canada; her institution has received research funding for her projects from Roche Canada and Astra-Zeneca Canada. Steven J.M. Jones has received project funding from Roche. Daniel J. Renouf disclosures include research funding and honoraria from Bayer and Roche, and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen, and Astra-Zeneca. Howard J. Lim has received honoraria from Eisai, Taiho, Roche, Lilly, BMS, Amgen, and Leo for consultant work and is an investigator on trials with Bayer, BMS, Lilly, Roche, Astra-Zeneca, and Amgen. Kasmintan Schrader has received research grant and honoraria funding from Astra-Zeneca and Pfizer. Sophie Sun has received research grant and honoraria funding from Astra-Zeneca and honoraria from BMS, Novartis, Pfizer, Purdue, Roche, and Takeda. Stephen Yip is an advisory board member for and has received travel allowance from Amgen, Astra-Zeneca, Bayer, Novartis, and Roche. Dean A. Regier has received honoraria from Roche Canada and Astra-Zeneca.